- Home
- BMY
as 11-19-2024 3:32pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 110.2B | IPO Year: | N/A |
| Target Price: | $53.92 | AVG Volume (30 days): | 11.5M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -3.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $61.08 | Next Earning Date: | 10-31-2024 |
| Revenue: | $47,435,000,000 | Revenue Growth: | 5.56% |
| Revenue Growth (this year): | 6.54% | Revenue Growth (next year): | -1.29% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Business Wire
9 hours ago
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Benzinga
a day ago
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
MT Newswires
a day ago
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight
Insider Monkey
a day ago
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
Pharmaceutical Technology
a day ago
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Morningstar Research
2 days ago
Analyst Report: Bristol-Myers Squibb Company
Barrons.com
3 days ago
Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
Morningstar Research
4 days ago
Analyst Report: Bristol-Myers Squibb Company
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.